Company profile: Orexo
1.1 - Company Overview
Company description
- Provider of pharmaceutical treatments and drug delivery technologies, including Zubsolv, a medication for opioid dependence commercialized in the US, and AmorphOX, a proprietary nasal delivery technology used to develop new pharmaceutical products.
Products and services
- AmorphOX: Proprietary nasal-delivery platform enabling development of new pharmaceutical products by producing intranasal drug administration systems for targeted applications
- Drug Delivery Technology Development: Orexo engineers improved treatments using proprietary drug-delivery technology to develop new pharmaceutical products for therapeutic applications
- Zubsolv: US-commercialized medication for opioid dependence that delivers treatment for opioid-use disorder to patients across the United States market
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orexo
Clearmind Medicine
HQ: Canada
Website
- Description: Provider of psychedelic medicine research and development, discovering and developing novel psychedelic-derived therapeutics for under-served health problems. Pipeline includes CMND-100, a MEAI-based oral capsule for Alcohol Use Disorder in Phase I/IIa, and 3-MMC for eating disorders. Holds exclusive worldwide rights to a patent-pending synthesis for addiction and mental disorders and 17 utility patent families (27 granted, 32 pending).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clearmind Medicine company profile →
Ionix Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Based in Cambridge, UK, Ionix Pharmaceuticals leverages proprietary drug targets and state-of-the-art chemistry to alleviate pain associated with trauma and operative procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ionix Pharmaceuticals company profile →
Serina Therapeutics
HQ: United States
Website
- Description: Provider of proprietary polymer-based drug delivery and therapeutics, including the POZ Platform for programmable, targeted, continuous small-molecule delivery (IV/SC/IM); SER-252 for advanced Parkinson’s Disease; CNS small-molecule conjugates; POZ-lipid LNPs for mRNA immunology; and ADCs that increase DAR to improve efficacy, addressing cancer, inflammation, pain and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serina Therapeutics company profile →
Arthex Biotech
HQ: Spain
Website
- Description: Provider of antisense RNA and anti-miR therapies for Myotonic Dystrophy, including a program targeting upregulated miRNA to address the disease’s root cause and improve delivery to muscle tissue, and early preclinical development of an innovative Type 1 Myotonic Dystrophy drug with in vitro toxicity and preliminary pharmacokinetic and pharmacodynamic studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arthex Biotech company profile →
Curemark
HQ: United States
Website
- Description: Provider of socially-driven biotechnology therapies for neurological diseases, developing CM-AT for Autism Spectrum Disorder (enhancing protein digestion and potentially restoring essential amino acids), CM-4612 (Phase III-ready for ADHD), CM-182 (enzyme replacement therapy for schizophrenia), CM-PK (for Parkinson’s, potentially affecting dopamine), and CM-1212 (for substance use disorders).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curemark company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orexo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orexo
2.2 - Growth funds investing in similar companies to Orexo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orexo
4.2 - Public trading comparable groups for Orexo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →